Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$56.53 +1.5%	$59.06	$42.52 ▼ $62.89	$115.28B	0.26	12.34 million shs	1.67 million shs
JAZZ Jazz Pharmaceuticals	$226.50 +1.3%	$193.90	$101.50 ▼ $230.40	$14.20B	0.27	1.00 million shs	130,270 shs
RPRX Royalty Pharma	$51.88 +0.4%	$47.86	$32.15 ▼ $52.14	$29.92B	0.4	3.51 million shs	420,695 shs
ZTS Zoetis	$76.07 -0.8%	$116.50	$75.11 ▼ $172.23	$31.89B	0.87	4.70 million shs	3.62 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-0.86%	-4.51%	-5.10%	-8.55%	+19.92%
JAZZ Jazz Pharmaceuticals	-0.97%	+10.30%	+15.14%	+35.01%	+128.62%
RPRX Royalty Pharma	+1.69%	+4.41%	+7.81%	+16.83%	+55.81%
ZTS Zoetis	-7.46%	-32.92%	-34.99%	-40.20%	-52.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$56.53 +1.5%	$59.06	$42.52 ▼ $62.89	$115.28B	0.26	12.34 million shs	1.67 million shs
JAZZ Jazz Pharmaceuticals	$226.50 +1.3%	$193.90	$101.50 ▼ $230.40	$14.20B	0.27	1.00 million shs	130,270 shs
RPRX Royalty Pharma	$51.88 +0.4%	$47.86	$32.15 ▼ $52.14	$29.92B	0.4	3.51 million shs	420,695 shs
ZTS Zoetis	$76.07 -0.8%	$116.50	$75.11 ▼ $172.23	$31.89B	0.87	4.70 million shs	3.62 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-0.86%	-4.51%	-5.10%	-8.55%	+19.92%
JAZZ Jazz Pharmaceuticals	-0.97%	+10.30%	+15.14%	+35.01%	+128.62%
RPRX Royalty Pharma	+1.69%	+4.41%	+7.81%	+16.83%	+55.81%
ZTS Zoetis	-7.46%	-32.92%	-34.99%	-40.20%	-52.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.37	Hold	$61.31	10.24% Upside
JAZZ Jazz Pharmaceuticals	2.83	Moderate Buy	$230.56	3.11% Upside
RPRX Royalty Pharma	3.00	Buy	$53.71	4.00% Upside
ZTS Zoetis	2.40	Hold	$141.25	84.35% Upside

Current Analyst Ratings Breakdown

Latest ZTS, BMY, RPRX, and JAZZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2026	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$130.00 ➝ $99.00
5/8/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$105.00
5/8/2026	ZTS Zoetis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$190.00 ➝ $130.00
5/7/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$245.00
5/7/2026	RPRX Royalty Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $66.00
5/7/2026	RPRX Royalty Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $58.00
5/6/2026	JAZZ Jazz Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$239.00
5/6/2026	JAZZ Jazz Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$220.00 ➝ $275.00
5/6/2026	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$252.00
5/6/2026	JAZZ Jazz Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$225.00 ➝ $234.00
5/6/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$195.00 ➝ $258.00

(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.19B	2.36	$8.05 per share	6.91	$9.09 per share	6.12
JAZZ Jazz Pharmaceuticals	$4.27B	3.29	$16.11 per share	13.88	$71.07 per share	3.15
RPRX Royalty Pharma	$2.38B	12.53	$4.86 per share	10.63	$16.83 per share	3.07
ZTS Zoetis	$9.47B	3.39	$7.00 per share	10.95	$7.56 per share	10.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$3.56	15.62	9.19	0.16	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
JAZZ Jazz Pharmaceuticals	-$356.15M	-$0.02	N/A	10.05	0.40	0.66%	14.56%	5.25%	N/A
RPRX Royalty Pharma	$770.95M	$1.47	35.14	9.44	1.40	33.88%	29.25%	14.71%	N/A
ZTS Zoetis	$2.67B	$6.03	12.71	10.19	1.29	27.80%	66.85%	18.79%	N/A

Latest ZTS, BMY, RPRX, and JAZZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ZTS Zoetis	$1.60	$1.53	-$0.07	$1.42	$2.30 billion	$2.26 billion
5/6/2026	Q1 2026	RPRX Royalty Pharma	$1.22	$1.30	+$0.08	$0.67	$881.69 million	$631.00 million
5/5/2026	Q1 2026	JAZZ Jazz Pharmaceuticals	$4.67	$6.34	+$1.67	$4.43	$978.66 million	$974.98 million
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion
3/31/2026	Q1 2026	JAZZ Jazz Pharmaceuticals	N/A	$6.34	N/A	$4.43	N/A	$1.07 billion
2/25/2026	Q4 2025	JAZZ Jazz Pharmaceuticals	$6.49	$6.64	+$0.15	$3.21	$1.17 billion	$1.20 billion
2/12/2026	Q4 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.37	$2.36 billion	$2.39 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	4.46%	+1.61%	70.79%	17 Years
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.81%	+24.01%	63.95%	5 Years
ZTS Zoetis	$2.12	2.79%	+20.11%	35.16%	14 Years

Latest RPRX, BMY, ZTS, and JAZZ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.88%	5/15/2026	5/15/2026	6/10/2026
3/2/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.23%	4/2/2026	4/2/2026	5/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.10	1.42	1.28
JAZZ Jazz Pharmaceuticals	0.95	2.04	1.85
RPRX Royalty Pharma	0.86	2.66	2.66
ZTS Zoetis	2.80	3.15	1.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
JAZZ Jazz Pharmaceuticals	89.14%
RPRX Royalty Pharma	54.35%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
JAZZ Jazz Pharmaceuticals	4.30%
RPRX Royalty Pharma	18.84%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
JAZZ Jazz Pharmaceuticals	2,890	62.74 million	60.05 million	Optionable
RPRX Royalty Pharma	80	576.86 million	468.18 million	Optionable
ZTS Zoetis	14,500	419.23 million	418.31 million	Optionable

RPRX, BMY, ZTS, and JAZZ Headlines

Recent News About These Companies

Rep. Gilbert Ray Cisneros, Jr. Sells Zoetis Inc. (NYSE:ZTS) Stock

May 12 at 5:00 AM | marketbeat.com

Zoetis Stock: Analyst Estimates & Ratings

May 11 at 10:51 AM | barchart.com

Zoetis (NYSE:ZTS) Sets New 1-Year Low on Analyst Downgrade

May 11 at 10:25 AM | marketbeat.com

16,056 Shares in Zoetis Inc. $ZTS Acquired by Kepler Cheuvreux Suisse SA

May 11 at 6:33 AM | marketbeat.com

Midwest Trust Co Has $11.79 Million Stake in Zoetis Inc. $ZTS

May 11 at 6:06 AM | marketbeat.com

Manning & Napier Advisors LLC Sells 382,864 Shares of Zoetis Inc. $ZTS

May 11 at 5:57 AM | marketbeat.com

Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?

May 10 at 9:51 AM | benzinga.com

Zoetis Q1 Review: Is A Darkened Outlook Cyclical Or Structural? (Rating Downgrade)

May 10 at 9:03 AM | seekingalpha.com

Zoetis Inc. $ZTS Shares Sold by UNIVEST FINANCIAL Corp

May 10 at 7:31 AM | marketbeat.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price

May 10 at 5:01 AM | americanbankingnews.com

Zoetis (NYSE:ZTS) Posts Earnings Results

May 9 at 5:14 PM | marketbeat.com

Zoetis Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 9 at 1:50 PM | finance.yahoo.com

Zoetis: Significant Patience Required

May 9 at 10:31 AM | seekingalpha.com

Zoetis cuts full-year profit outlook as price-sensitive pet owners reduce vet visits

May 9 at 8:35 AM | msn.com

Zoetis (ZTS) Q1 2026 Earnings Transcript

May 9 at 8:35 AM | finance.yahoo.com

Zoetis cuts 2026 outlook as U.S. sales fall in Q1

May 9 at 8:35 AM | seekingalpha.com

Zoetis (ZTS) Is Down 24.1% After Cutting 2026 Guidance On Softer U.S. Pet Demand – Has The Bull Case Changed?

May 9 at 8:35 AM | finance.yahoo.com

Truist Financial Corp Has $10.08 Million Position in Zoetis Inc. $ZTS

May 9 at 7:08 AM | marketbeat.com

Generali Asset Management SPA SGR Decreases Position in Zoetis Inc. $ZTS

May 9 at 5:59 AM | marketbeat.com

Zoetis (NYSE:ZTS) Price Target Cut to $130.00 by Analysts at JPMorgan Chase & Co.

May 8, 2026 | marketbeat.com

Zoetis Inc. $ZTS Holdings Lowered by Premier Fund Managers Ltd

May 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX, BMY, ZTS, and JAZZ Company Descriptions

Bristol Myers Squibb NYSE:BMY

$56.53 +0.86 (+1.54%)

As of 11:15 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Jazz Pharmaceuticals NASDAQ:JAZZ

$226.50 +2.89 (+1.29%)

As of 11:15 AM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Royalty Pharma NASDAQ:RPRX

$51.88 +0.23 (+0.44%)

As of 11:15 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis NYSE:ZTS

$76.07 -0.60 (-0.78%)

As of 11:15 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, BMY, RPRX, and JAZZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, BMY, RPRX, and JAZZ Earnings

Compare Dividends

Latest RPRX, BMY, ZTS, and JAZZ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPRX, BMY, ZTS, and JAZZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX, BMY, ZTS, and JAZZ Company Descriptions

Bristol Myers Squibb NYSE:BMY

Jazz Pharmaceuticals NASDAQ:JAZZ

Royalty Pharma NASDAQ:RPRX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, BMY, RPRX, and JAZZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, BMY, RPRX, and JAZZ Earnings

Compare Dividends

Latest RPRX, BMY, ZTS, and JAZZ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPRX, BMY, ZTS, and JAZZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX, BMY, ZTS, and JAZZ Company Descriptions

Bristol Myers Squibb NYSE:BMY

Jazz Pharmaceuticals NASDAQ:JAZZ

Royalty Pharma NASDAQ:RPRX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools